Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07755020
Recruiting Observational

Nitride-Based Raman Biochip for Lung Cancer Diagnosis and Monitoring

NCT07755020 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Taichung Veterans General Hospital
Phase
Observational
Started
2025-08-04
Last updated
2026-08-10

Condition(s) studied

Lung Cancer (Diagnosis)Lung Neoplasms

Study summary

This prospective, multicenter observational study aims to evaluate the diagnostic and clinical monitoring performance of a nitride-based Raman biochip in participants with and without lung cancer. Peripheral blood samples will be collected and analyzed using the Raman biochip to characterize molecular spectral patterns and assess their association with the current standard diagnosis of lung cancer.

The study plans to enroll 2,000 participants with pathologically confirmed lung cancer and 1,000 participants without lung cancer. Diagnostic performance will be evaluated using measures including sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic curve analysis. Exploratory analyses will assess performance according to lung cancer histological subtype, disease stage, and longitudinal clinical status.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Lung Cancer Group: 1. Age 18 years or older. 2. Underwent low-dose computed tomography or chest computed tomography within the previous 2 years. 3. Pathologically confirmed lung cancer. 4. Histological diagnosis of adenocarcinoma, squamous cell carcinoma, or small cell lung cancer, with TNM stage determined by a thoracic physician. 5. Willing to provide approximately 20 mL of peripheral blood annually for 3 years. 6. Able to understand the study information and provide written informed consent. 7. Agrees to linkage of study data with relevant health insurance and mortality databases, as applicable. Non-Lung Cancer Group: 1. Age 18 years or older. 2. Underwent low-dose computed tomography or chest computed tomography within the previous 2 years. 3. No pulmonary nodule or ground-glass lesion, or a pulmonary nodule or ground-glass lesion smaller than 0.4 cm. 4. May have a chronic pulmonary disease, including chronic obstructive pulmonary disease, asthma, bronchiectasis, or pulmonary fibrosis. 5. Willing to provide one peripheral blood sample of approximately 20 mL. 6. Able to understand the study information and provide written informed consent. 7. Agrees to linkage of study data with relevant health insurance and mortality databases, as applicable. Exclusion Criteria: * 1\. Younger than 18 years of age. 2. Unable to understand the study information or provide written informed consent. 3\. For the non-lung cancer group, presence of a pulmonary nodule or ground-glass lesion greater than 0.4 cm. 4\. Unwilling to provide a peripheral blood sample. 5. Unwilling to permit linkage with the National Health Insurance research data system.

Primary outcome measure(s)

  • Diagnostic Accuracy of the Nitride-Based Raman Biochip for Lung Cancer — At analysis of the blood sample collected at study enrollment
    The ability of the Raman spectral signature generated by the nitride-based Raman biochip to distinguish participants with pathologically confirmed lung cancer from participants without lung cancer will be evaluated using the area under the receiver operating characteristic curve.

Trial sites (1)

FacilityCityRegionStatus
Taichung Veterans General Hospital Taichung Taiwan Recruiting

More Taichung Veterans General Hospital trials in Taiwan

Taiwan Severe Asthma Biologic Registry Recruiting
Lyophilized Platelet-Rich Plasma Lysate vs Dextrose Prolotherapy for Partial Rotator Cuff Tears Active, not recruiting
3D Modeling for Detecting Locally Advanced Rectal Cancer With Positive Circumferential Resection Margin Starting soon
Optimized Diagnosis and Precision Medicine of MODY Recruiting
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial Recruiting

Other trials for the same condition

The Effects of Low Intensity Endurance Exercise on Improving Mitochondrial Function, Cell Bioelectrical Impedance Phase Angle, Fatigue and Quality of Life in Lung Cancer Patients With Cancer-related Fatigue Recruiting
3D-US Construct on Volumetric Assessment of Lung Disease & Clinical Application Starting soon
3D Virtual Resection for Predicting Lung Function in VATS Recruiting
The Effects of Low-Intensity Endurance Exercise on Improving Fatigue, Sleep, Quality of Life, Mitochondrial Function, Cellular Bioelectrical Impedance Phase Angle, and Predictors of Exercise Adherence in Patients With Lung Cancer Recruiting
Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07755020 on ClinicalTrials.gov ↗ ← All trials in Taiwan